Omnicare — Q3 2010 Earnings Presentation
22 slides from Omnicare's earnings presentation, Nov 2, 2010
Slide 1: November 2, 2010
November 2, 2010
Slide 2: Forward-Looking Statements
Except for historical information discussed, the statements made today are forward-looking statements that involve risks and uncertainties. Investors are cautioned that such statements are only predictions and that actual events or results may differ materially. These forward-looking statements spea
Slide 3: Omnicare Today: A Senior Care Pharmacy Services Company
Industry leader 47 states, District of Columbia and Canada 120 million prescriptions dispensed per year Nation’s largest provider of hospice pharmacy Global contract research organization Omnicare Today… A Senior Care Pharmacy Services Company – –
Slide 4: Omnicare Growth Drivers
Demographic trends Pharmaceutical market trends Strategic objectives Omnicare Growth Drivers
Slide 5: Aging Population Shaping Healthcare
Life expectancy continues to lengthen Significant population mix shift towards seniors Source: U.S. Census Bureau Demographic Trends Aging Population Shaping Healthcare
Slide 6: Pharmaceutical Market Trends
Branded drugs Major market shift to generic drugs Development and use of biologics increasing Pharmaceutical Market Trends
Slide 7: Increasing Utilization of Generics
(1) Generic prescriptions dispensed as a percent of total scripts Brand to Generic Drugs Increasing Utilization of Generics
Slide 8: Major Shift to Generic Drugs: Benefits
Buy-side margin Favorable impact on working capital Top 100 generic drug analysis Major Shift to Generic Drugs Benefits
Slide 9: Generic Drugs Long-Term Trends
Top 100 generics based on revenue 94% of these older generics providing positive contribution relative to brand Generic Drugs Long-Term Trends
Slide 10: 2010-2013 Potential Patent Expirations
(1) All generic launches are subject to change due to litigation or pediatric exclusivity. (2) Drugs already launched shown in gray and italics 2010 2011 2012 2013 Arimidex Fazaclo Actos Aciphex Cozaar Femara Diovan Asacol Effexor ER Gabitril Exelon Patch Avodart Exelon Caps Levaquin Geodon Cymbalta
Slide 11: Specialty Pharmaceuticals: A Growth Industry
(1) Source: EvaluatePharma Pharmaceutical Market Share (1) by Drug Type • Mail order • Oncology and multiple sclerosis Outsourced services for biotechnology firms Omnicare’s institutional pharmacies Conventional Drugs, 72% Other, 19% Omnicare’s Positioning Within Specialty Pharmaceuticals… Specialty
Slide 12: Strategic Objectives
Productivity improvements Cost-reduction initiatives Customer growth Skilled nursing facilities (SNFs) Assisted living facilities (ALFs) Other institutional settings Specialty pharmacy Strategic Objectives – – – –
Slide 13: Transitioning to an Operations-Driven Company
Cultural transformation Instill collaborative environment, encourage employee innovation Revamp budgeting process Reinforce a commitment to compliance Reallocation of resources Align employee interests Reshape the organization, bringing it closer to the customer Improve accountability with regional
Slide 14: Cost-Reduction Initiatives
Drug purchasing Leveraging brand and generic drug purchasing power Strategic sourcing Capitalizing on scale with non-drug purchases Operating initiatives Hub-and-spoke network, new technologies, best practices (1) P&L savings realized for trailing four quarters through the third quarter of 2010. Pro
Slide 15: Initiatives Focused on Organic Growth
Enhance the customer experience Align customer retention with incentive programs Proactive vs. reactive approach to customer service Reposition leading technology offering Improve selling effectiveness Re-engage sales consulting group Improve coordination of selling process Revamped incentive progra
Slide 16: Broadening Markets
Assisted living market CCRCs, independent living Mental health market, rural hospitals, prisons Customer Growth Broadening Markets
Slide 17: Focus on Assisted Living Opportunity
Assisted Living: Three-Pronged Growth Opportunity Customer Growth Focus on Assisted Living Opportunity
Slide 18: Specialty Pharmacy: Growth Outside Institutional Setting
Omnicare specialty pharmacy growth rates have outpaced robust industry growth rates…but opportunities exist to further accelerate growth through: Addition of new leadership Tighter coordination of efforts Penetrate additional disease states (for ACS) Primary disease states currently multiple scleros
Slide 19: Third Quarter 2010 Highlights
Scripts dispensed increased 1.3% sequentially – One additional calendar day in 3Q 2010 as compared with 2Q 2010 – Number of beds served up sequentially – Utilization stable – Census was lower, although rate of decline improved from 2Q 2010 Qtr. ending number of beds served (1) up 32,000 sequentially
Slide 20: Capital Returned to Shareholders
(1) Cumulative % Returned = (YTD Dividends Paid + YTD Share Repurchases) / 12/31/09 Market Capitalization of $2,908.4 million. Capital Returned to Shareholders
Slide 21: Omnicare's Fundamental Value Drivers
Favorable industry dynamics Industry leading position Scale business Solid financial position Substantial cash flow generator Enhancing efficiency of operations Opportunities to leverage core business Omnicare’s Fundamental Value Drivers
Slide 22: November 2, 2010
November 2, 2010